Arild Opheim

471 total citations
17 papers, 354 citations indexed

About

Arild Opheim is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Arild Opheim has authored 17 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Public Health, Environmental and Occupational Health, 12 papers in Epidemiology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Arild Opheim's work include Opioid Use Disorder Treatment (16 papers), Substance Abuse Treatment and Outcomes (12 papers) and Prenatal Substance Exposure Effects (5 papers). Arild Opheim is often cited by papers focused on Opioid Use Disorder Treatment (16 papers), Substance Abuse Treatment and Outcomes (12 papers) and Prenatal Substance Exposure Effects (5 papers). Arild Opheim collaborates with scholars based in Norway, Puerto Rico and Bangladesh. Arild Opheim's co-authors include Kristin Klemmetsby Solli, Lars Tanum, Nikolaj Kunøe, Zill-E-Huma Latif, Jūratė Šaltytė Benth, Peter Krajči, Sven Andréasson, Peter Prescott, Lars Thore Fadnes and Jon Mordal and has published in prestigious journals such as Biological Psychiatry, Addiction and JAMA Psychiatry.

In The Last Decade

Arild Opheim

17 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arild Opheim Norway 8 282 231 77 54 51 17 354
Zill-E-Huma Latif Norway 7 271 1.0× 221 1.0× 75 1.0× 54 1.0× 51 1.0× 12 328
Kristin Klemmetsby Solli Norway 10 329 1.2× 265 1.1× 83 1.1× 61 1.1× 62 1.2× 30 406
Oscar D’Agnone United Kingdom 8 199 0.7× 145 0.6× 46 0.6× 63 1.2× 52 1.0× 15 296
Mirsada Serdarevic United States 7 197 0.7× 97 0.4× 97 1.3× 59 1.1× 60 1.2× 15 335
Thilo Beck Switzerland 10 190 0.7× 178 0.8× 37 0.5× 89 1.6× 31 0.6× 12 360
Kaitlyn Mishlen United States 8 216 0.8× 165 0.7× 74 1.0× 111 2.1× 25 0.5× 11 293
Wolfgang Gombas Austria 8 300 1.1× 188 0.8× 108 1.4× 77 1.4× 47 0.9× 11 370
Jean Falcioni United States 7 237 0.8× 172 0.7× 58 0.8× 83 1.5× 38 0.7× 8 336
Caroline Yoo United States 9 169 0.6× 135 0.6× 60 0.8× 36 0.7× 25 0.5× 19 262

Countries citing papers authored by Arild Opheim

Since Specialization
Citations

This map shows the geographic impact of Arild Opheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arild Opheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arild Opheim more than expected).

Fields of papers citing papers by Arild Opheim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arild Opheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arild Opheim. The network helps show where Arild Opheim may publish in the future.

Co-authorship network of co-authors of Arild Opheim

This figure shows the co-authorship network connecting the top 25 collaborators of Arild Opheim. A scholar is included among the top collaborators of Arild Opheim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arild Opheim. Arild Opheim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Mordal, Jon, John‐Kåre Vederhus, Arild Opheim, et al.. (2025). High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study. Addiction Science & Clinical Practice. 20(1). 50–50. 1 indexed citations
2.
Opheim, Arild, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.. (2023). Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial. Contemporary Clinical Trials. 135. 107360–107360. 2 indexed citations
3.
Opheim, Arild, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.. (2022). Risk of Relapse to Non-Opioid Addictive Substances Among Opioid Dependent Patients Treated with an Opioid Receptor Antagonist or a Partial Agonist: A Randomized Clinical Trial. SSRN Electronic Journal. 1 indexed citations
4.
Fadnes, Lars Thore, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.. (2021). The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. European Addiction Research. 28(1). 56–67. 5 indexed citations
5.
Opheim, Arild, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.. (2021). Risk of Relapse Among Opioid‐Dependent Patients Treated With Extended‐Release Naltrexone or Buprenorphine‐Naloxone: A Randomized Clinical Trial. American Journal on Addictions. 30(5). 453–460. 4 indexed citations
6.
Solli, Kristin Klemmetsby, Arild Opheim, Zill-E-Huma Latif, et al.. (2020). Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone. Addiction. 116(8). 2084–2093. 10 indexed citations
7.
Solli, Kristin Klemmetsby, Nikolaj Kunøe, Zill-E-Huma Latif, et al.. (2019). Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. European Addiction Research. 25(6). 303–309. 9 indexed citations
8.
Tanum, Lars, Zill-E-Huma Latif, Kristin Klemmetsby Solli, et al.. (2019). T212. No Increase in Chronic Pain Among Opioid-Dependent Individuals Randomized to Treatment With Extended-Release Naltrexone Compared to Buprenorphine-Naloxone. Biological Psychiatry. 85(10). S211–S212. 1 indexed citations
9.
Latif, Zill-E-Huma, Kristin Klemmetsby Solli, Arild Opheim, et al.. (2019). No increased pain among opioid‐dependent individuals treated with extended‐release naltrexone or buprenorphine‐naloxone: A 3‐month randomized study and 9‐month open‐treatment follow‐up study. American Journal on Addictions. 28(2). 77–85. 23 indexed citations
10.
Tanum, Lars, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.. (2018). S273. The Effectiveness of Injectable Extended Release Naltrexone Versus Daily Buprenorphine-Naloxone for Opioid Dependence in Short and Long Term Treatment. Biological Psychiatry. 83(9). S454–S454. 4 indexed citations
11.
Latif, Zill-E-Huma, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.. (2018). Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. JAMA Psychiatry. 76(2). 127–127. 46 indexed citations
12.
Solli, Kristin Klemmetsby, Zill-E-Huma Latif, Arild Opheim, et al.. (2018). Effectiveness, safety and feasibility of extended‐release naltrexone for opioid dependence: a 9‐month follow‐up to a 3‐month randomized trial. Addiction. 113(10). 1840–1849. 24 indexed citations
13.
Tanum, Lars, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.. (2017). Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. JAMA Psychiatry. 74(12). 1197–1197. 178 indexed citations
14.
15.
Kunøe, Nikolaj, et al.. (2016). Interest in Extended Release Naltrexone among Opioid Users. European Addiction Research. 22(6). 301–305. 6 indexed citations
16.
Kunøe, Nikolaj, et al.. (2016). Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacology and Toxicology. 17(1). 18–18. 22 indexed citations
17.
Opheim, Arild, et al.. (2009). The effects of training medical students in motivational interviewing. Health Education Journal. 68(3). 170–178. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zill-E-Huma Latif Breakdown of academic impact, for papers by Kristin Klemmetsby Solli Breakdown of academic impact, for papers by Oscar D’Agnone Breakdown of academic impact, for papers by Mirsada Serdarevic Breakdown of academic impact, for papers by Thilo Beck Breakdown of academic impact, for papers by Kaitlyn Mishlen Breakdown of academic impact, for papers by Wolfgang Gombas Breakdown of academic impact, for papers by Jean Falcioni Breakdown of academic impact, for papers by Caroline Yoo
Rankless by CCL
2026